Practical recommendations for the early use of m-TOR inhibitors (sirolimus) in renal transplantation
Por:
Campistol, JM, Cockwell, P, Diekmann, F, Donati, D, Guirado, L, Herlenius, G, Mousa, D, Pratschke, J, Millan, JCRS
Publicada:
1 jul 2009
Resumen:
m-TOR inhibitors (e.g. sirolimus) are well-tolerated immunosuppressants used in renal transplantation for prophylaxis of organ rejection, and are associated with long-term graft survival. Early use of sirolimus is often advocated by clinicians, but this may be associated with a number of side-effects including impaired wound-healing, lymphoceles and delayed graft function. As transplant clinicians with experience in the use of sirolimus, we believe such side-effects can be limited by tailored clinical management. We present recommendations based on published literature and our clinical experience. Furthermore, guidance is provided on sirolimus use during surgery, both at transplantation and for subsequent operations.
Filiaciones:
Campistol, JM:
Hosp Clin Barcelona, Unidad Transplante Renal, Barcelona 08036, Spain
Cockwell, P:
Univ Hosp Birmingham, Dept Nephrol, Birmingham, W Midlands, England
Univ Birmingham, Div Med Sci, Birmingham, W Midlands, England
Diekmann, F:
Dept Nephrol, Berlin, Germany
Donati, D:
Azienda Osped, Hosp Osped Circolo & Fdn Macchi, Varese, Italy
Guirado, L:
Fundacio Puigvert, Renal Transplant Unit, Barcelona, Spain
Herlenius, G:
Sahlgrens Univ Hosp, Dept Transplantat & Liver Surg, Gothenburg, Sweden
Mousa, D:
Riyadh Mil Hosp, Renal Transplant Programme, Riyadh, Saudi Arabia
Pratschke, J:
Charite Univ Med Berlin, Dept Gen Visceral & Transplantat Surg, D-13353 Berlin, Germany
Millan, JCRS:
Hosp Univ Valdecilla, Serv Nefrol, Santander, Spain
|